Navigation Links
Alzheimer's Drug Discovery Foundation Hosts 10th International Conference on Alzheimer's Drug Discovery - September 14-15
Date:9/1/2009

Latest Trends and Research Released on Alzheimer's Disease by Academic and Biotech Industry Scientists

NEW YORK, Sept. 1 /PRNewswire-USNewswire/ -- The 10th International Conference on Alzheimer's Drug Discovery, hosted by the Alzheimer's Drug Discovery Foundation and the only scientific conference focusing solely on the discovery and development of innovative drugs targeting Alzheimer's disease and related dementias, will convene September 14-15, 2009 at the Hyatt Regency in Jersey City, N.J.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090805/DC57332LOGO)

More than 30 leading international experts from academia and early-stage biotechnology companies will present and discuss their most current research. The meeting draws an audience of academic and industry scientists engaged in drug discovery research for neurodegenerative diseases. Because of ADDF's venture philanthropy focus, the conference is also open to business development and licensing professionals, alliance management professionals, venture capitalists, and other investors in biotechnology.

"We are proud to feature the accomplishments of our funded investigators and other researchers working on innovative approaches to drug discovery for Alzheimer's disease and related dementias," says Howard Fillit, MD, Executive Director of Alzheimer's Drug Discovery Foundation. "Our sole focus is accelerating the discovery of effective new treatments for Alzheimer's disease- bridging the gap that currently exists between basic research and later-stage drug development.

The conference program will focus on four major areas of study:

Neuroprotection and Prevention

Chair: Dr. Frank Longo, MD, PhD, Stanford University

Anti-Amyloid and Protein Misfolding

Chair: Michael Wolfe, PhD, Brigham and Women's Hospital

Anti-Tangles and Frontotemporal Dementia

Chair: Jeff Kuret, PhD, Ohio State University

Alternative Strategies: New Targets for Alzheimer's Disease Therapy

Chair: Diana Shineman, PhD, Alzheimer's Drug Discovery Foundation

The program will feature two plenary sessions: "Bridging Neurocognitive Aging and Disease Modification," by Michaela Gallagher, PhD, Johns Hopkins; and "TDP-43 as a New Target for Neurodegenerative Disease," by Virginia Lee, PhD, MBA, University of Pennsylvania.

The Alzheimer's Drug Discovery Foundation will also present the 2009 ADDF Young Investigators Scholarships, highly prestigious scholarships recognizing the early research achievements of ten younger scientists from academia.

The 10th International Conference on Alzheimer's Drug Discovery is sponsored by Pfizer Inc.; Elan Pharmaceuticals; Martek Biosciences Corporation; Schering-Plough; Allon Therapeutics, Inc.; JSW Lifesciences; Abbott; The American Journal of Geriatric Pharmacotherapy; Apredica; Intra-Cellular Therapies, Inc.; and Rhenovia Pharma.

For Conference Participants: To view the complete program schedule, to apply to register for the conference, and for information on accommodations, visit www.alzdiscovery.org.

About the Alzheimer's Drug Discovery Foundation

ADDF (www.alzdiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. We award grants to leading scientists conducting breakthrough drug discovery research. ADDF uses a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage development, using any return on investment to support new research. Since 1998, we have received over 1,600 requests to fund new ideas for Alzheimer's drugs. For all, we provided expert reviews and recommendations to advance their programs. We granted more than $35 million to fund more than 240 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 12 countries. The ADDF Website carries the latest, vetted news on Alzheimer's disease, updated weekly.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
2. Allegiance Equity Corporation announces collaboration with Canadian Dairy Commission and Guelph Food Technologies Corporation for Alzheimers and Dementia formulation GG-XT
3. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
4. Discovery of natural odors could help develop mosquito repellents
5. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
6. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
7. SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS
8. New method may accelerate drug discovery for difficult diseases like Parkinsons
9. Novel drug discovery tool could identify promising new therapies for Parkinsons disease
10. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
11. Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 Elekta is ... update to its industry-leading treatment planning software, is available ... Monaco version 5.11 provides significant performance ... calculation speeds up to four times faster than in ... the industry,s gold standard Monte Carlo ...
(Date:4/28/2016)... YORK , April 28, 2016 ... acceleration company reports the Company,s CEO  was featured ... titled Accelerators Enter When VCs Fear To Tread: ... Science Leader magazine is an essential ... for everything from emerging biotechs to Big Pharmas. ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week on May 5 ... first-in-class technologies for tissue stem cell counting and expansion to gene-editing scientists and ... & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of most gene-editing ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... hold an open house for regional manufacturers at its Maple Grove, Minnesota technical ... Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading suppliers of tooling, ...
Breaking Biology Technology:
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
(Date:3/15/2016)... Yissum Research Development Company of the Hebrew University ... University, announced today the formation of Neteera Technologies ... biological indicators. Neteera Technologies has completed its first round ... Neteera,s ... from sweat ducts, enables reliable and speedy biometric identification, ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):